Opposite effects of pioglitazone and rosiglitazone on mitochondrial respiration in skeletal muscle of patients with type 2 diabetes

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Opposite effects of pioglitazone and rosiglitazone on mitochondrial respiration in skeletal muscle of patients with type 2 diabetes. / Rabøl, R; Boushel, R; Almdal, T; Hansen, C.N.; Ploug, T; Haugaard, Steen Bendix; Prats, C; Madsbad, S; Dela, F; Rabøl, R; Boushel, R; Almdal, T; Hansen, C N; Ploug, T; Haugaard, S B; Prats, C; Madsbad, S; Dela, F.

I: Diabetic Medicine, Bind 12, Nr. 9, 2010, s. 806-14.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Rabøl, R, Boushel, R, Almdal, T, Hansen, CN, Ploug, T, Haugaard, SB, Prats, C, Madsbad, S, Dela, F, Rabøl, R, Boushel, R, Almdal, T, Hansen, CN, Ploug, T, Haugaard, SB, Prats, C, Madsbad, S & Dela, F 2010, 'Opposite effects of pioglitazone and rosiglitazone on mitochondrial respiration in skeletal muscle of patients with type 2 diabetes', Diabetic Medicine, bind 12, nr. 9, s. 806-14. https://doi.org/10.1111/j.1463-1326.2010.01237.x, https://doi.org/10.1111/j.1463-1326.2010.01237.x

APA

Rabøl, R., Boushel, R., Almdal, T., Hansen, C. N., Ploug, T., Haugaard, S. B., ... Dela, F. (2010). Opposite effects of pioglitazone and rosiglitazone on mitochondrial respiration in skeletal muscle of patients with type 2 diabetes. Diabetic Medicine, 12(9), 806-14. https://doi.org/10.1111/j.1463-1326.2010.01237.x, https://doi.org/10.1111/j.1463-1326.2010.01237.x

Vancouver

Rabøl R, Boushel R, Almdal T, Hansen CN, Ploug T, Haugaard SB o.a. Opposite effects of pioglitazone and rosiglitazone on mitochondrial respiration in skeletal muscle of patients with type 2 diabetes. Diabetic Medicine. 2010;12(9):806-14. https://doi.org/10.1111/j.1463-1326.2010.01237.x, https://doi.org/10.1111/j.1463-1326.2010.01237.x

Author

Rabøl, R ; Boushel, R ; Almdal, T ; Hansen, C.N. ; Ploug, T ; Haugaard, Steen Bendix ; Prats, C ; Madsbad, S ; Dela, F ; Rabøl, R ; Boushel, R ; Almdal, T ; Hansen, C N ; Ploug, T ; Haugaard, S B ; Prats, C ; Madsbad, S ; Dela, F. / Opposite effects of pioglitazone and rosiglitazone on mitochondrial respiration in skeletal muscle of patients with type 2 diabetes. I: Diabetic Medicine. 2010 ; Bind 12, Nr. 9. s. 806-14.

Bibtex

@article{8ba6b8f0b4d411df825b000ea68e967b,
title = "Opposite effects of pioglitazone and rosiglitazone on mitochondrial respiration in skeletal muscle of patients with type 2 diabetes",
abstract = "AIM: Skeletal muscle insulin resistance has been linked to mitochondrial dysfunction. We examined how improvements in muscular insulin sensitivity following rosiglitazone (ROSI) or pioglitazone (PIO) treatment would affect muscle mitochondrial function in patients with type 2 diabetes mellitus (T2DM). METHODS: Muscle biopsies were obtained from 21 patients with T2DM before and after 12 weeks on either ROSI (4 mg once daily) [n = 12; age, 59.2 +/- 2.2 years; body mass index (BMI), 29.6 +/- 0.7 kg/m(2)] or PIO (30 mg once daily) (n = 9; age, 56.3 +/- 2.4 years; BMI, 29.5 +/- 1.5 kg/m(2)). An age- and BMI-matched control group was also included (n = 8; age, 61.8 +/- 2.3 years; BMI, 28.4 +/- 0.6 kg/m(2)). Insulin sensitivity, citrate synthase- and beta-hydroxyacyl-CoA-dehydrogenase (HAD) activity, intramuscular triglyceride (IMTG) and protein content of complexes I-IV were measured, while mitochondrial respiration per milligram muscle was measured in saponin-treated skinned muscle fibres using high-resolution respirometry. RESULTS: Mitochondrial respiration per milligram muscle was lower in T2DM compared to controls at baseline and decreased during ROSI treatment but increased during PIO treatment. Citrate synthase activity and average protein content of complexes I-IV were unchanged in the ROSI group, but protein content of complexes II and III increased during PIO treatment. Insulin sensitivity improved in all patients, but IMTG levels were unchanged. CONCLUSIONS: We show opposite effects of ROSI and PIO on mitochondrial respiration, and also show that insulin sensitivity can be improved independently of changes in mitochondrial respiration. We confirm that mitochondrial respiration is reduced in T2DM compared to age- and BMI-matched control subjects.",
author = "R Rab{\o}l and R Boushel and T Almdal and C.N. Hansen and T Ploug and Haugaard, {Steen Bendix} and C Prats and S Madsbad and F Dela and R Rab{\o}l and R Boushel and T Almdal and Hansen, {C N} and T Ploug and Haugaard, {S B} and C Prats and S Madsbad and F Dela",
year = "2010",
doi = "10.1111/j.1463-1326.2010.01237.x",
language = "English",
volume = "12",
pages = "806--14",
journal = "Diabetic Medicine",
issn = "0742-3071",
publisher = "Wiley-Blackwell",
number = "9",

}

RIS

TY - JOUR

T1 - Opposite effects of pioglitazone and rosiglitazone on mitochondrial respiration in skeletal muscle of patients with type 2 diabetes

AU - Rabøl, R

AU - Boushel, R

AU - Almdal, T

AU - Hansen, C.N.

AU - Ploug, T

AU - Haugaard, Steen Bendix

AU - Prats, C

AU - Madsbad, S

AU - Dela, F

AU - Rabøl, R

AU - Boushel, R

AU - Almdal, T

AU - Hansen, C N

AU - Ploug, T

AU - Haugaard, S B

AU - Prats, C

AU - Madsbad, S

AU - Dela, F

PY - 2010

Y1 - 2010

N2 - AIM: Skeletal muscle insulin resistance has been linked to mitochondrial dysfunction. We examined how improvements in muscular insulin sensitivity following rosiglitazone (ROSI) or pioglitazone (PIO) treatment would affect muscle mitochondrial function in patients with type 2 diabetes mellitus (T2DM). METHODS: Muscle biopsies were obtained from 21 patients with T2DM before and after 12 weeks on either ROSI (4 mg once daily) [n = 12; age, 59.2 +/- 2.2 years; body mass index (BMI), 29.6 +/- 0.7 kg/m(2)] or PIO (30 mg once daily) (n = 9; age, 56.3 +/- 2.4 years; BMI, 29.5 +/- 1.5 kg/m(2)). An age- and BMI-matched control group was also included (n = 8; age, 61.8 +/- 2.3 years; BMI, 28.4 +/- 0.6 kg/m(2)). Insulin sensitivity, citrate synthase- and beta-hydroxyacyl-CoA-dehydrogenase (HAD) activity, intramuscular triglyceride (IMTG) and protein content of complexes I-IV were measured, while mitochondrial respiration per milligram muscle was measured in saponin-treated skinned muscle fibres using high-resolution respirometry. RESULTS: Mitochondrial respiration per milligram muscle was lower in T2DM compared to controls at baseline and decreased during ROSI treatment but increased during PIO treatment. Citrate synthase activity and average protein content of complexes I-IV were unchanged in the ROSI group, but protein content of complexes II and III increased during PIO treatment. Insulin sensitivity improved in all patients, but IMTG levels were unchanged. CONCLUSIONS: We show opposite effects of ROSI and PIO on mitochondrial respiration, and also show that insulin sensitivity can be improved independently of changes in mitochondrial respiration. We confirm that mitochondrial respiration is reduced in T2DM compared to age- and BMI-matched control subjects.

AB - AIM: Skeletal muscle insulin resistance has been linked to mitochondrial dysfunction. We examined how improvements in muscular insulin sensitivity following rosiglitazone (ROSI) or pioglitazone (PIO) treatment would affect muscle mitochondrial function in patients with type 2 diabetes mellitus (T2DM). METHODS: Muscle biopsies were obtained from 21 patients with T2DM before and after 12 weeks on either ROSI (4 mg once daily) [n = 12; age, 59.2 +/- 2.2 years; body mass index (BMI), 29.6 +/- 0.7 kg/m(2)] or PIO (30 mg once daily) (n = 9; age, 56.3 +/- 2.4 years; BMI, 29.5 +/- 1.5 kg/m(2)). An age- and BMI-matched control group was also included (n = 8; age, 61.8 +/- 2.3 years; BMI, 28.4 +/- 0.6 kg/m(2)). Insulin sensitivity, citrate synthase- and beta-hydroxyacyl-CoA-dehydrogenase (HAD) activity, intramuscular triglyceride (IMTG) and protein content of complexes I-IV were measured, while mitochondrial respiration per milligram muscle was measured in saponin-treated skinned muscle fibres using high-resolution respirometry. RESULTS: Mitochondrial respiration per milligram muscle was lower in T2DM compared to controls at baseline and decreased during ROSI treatment but increased during PIO treatment. Citrate synthase activity and average protein content of complexes I-IV were unchanged in the ROSI group, but protein content of complexes II and III increased during PIO treatment. Insulin sensitivity improved in all patients, but IMTG levels were unchanged. CONCLUSIONS: We show opposite effects of ROSI and PIO on mitochondrial respiration, and also show that insulin sensitivity can be improved independently of changes in mitochondrial respiration. We confirm that mitochondrial respiration is reduced in T2DM compared to age- and BMI-matched control subjects.

U2 - 10.1111/j.1463-1326.2010.01237.x

DO - 10.1111/j.1463-1326.2010.01237.x

M3 - Journal article

C2 - 20649633

VL - 12

SP - 806

EP - 814

JO - Diabetic Medicine

JF - Diabetic Medicine

SN - 0742-3071

IS - 9

ER -

ID: 21693273